{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T22:10:21Z","timestamp":1760825421357,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jocn.2022.06.019","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T14:29:38Z","timestamp":1657117778000},"page":"44-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cannabis use in patients with Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay"],"prefix":"10.1016","volume":"103","author":[{"given":"William","family":"Beauchesne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Ouellet-Dupuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc-Antoine","family":"Frigon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Savard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Gagn\u00e9-Ouellet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jocn.2022.06.019_b0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1017\/S0317167100024793","article-title":"Autosomal recessive spastic ataxia of Charlevoix-Saguenay","volume":"5","author":"Bouchard","year":"1978","journal-title":"Canad J Neurol Sci"},{"key":"10.1016\/j.jocn.2022.06.019_b0010","unstructured":"Vermeer S, van de Warrenburg BP, Kamsteeg EJ, et al. ARSACS. 2003 Dec 9 [Updated 2020 Jan 2]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1255\/."},{"issue":"1","key":"10.1016\/j.jocn.2022.06.019_b0015","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev.genom.2.1.69","article-title":"Human genetics: lessons from Quebec populations","volume":"2","author":"Scriver","year":"2001","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.jocn.2022.06.019_b0020","first-page":"970","article-title":"Variability of the genetic contribution of Quebec population founders associated to some deleterious genes","volume":"56","author":"Heyer","year":"1995","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jocn.2022.06.019_b0025","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13023-018-0898-z","article-title":"From motor performance to participation: a quantitative descriptive study in adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay","volume":"13","author":"Gagnon","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jocn.2022.06.019_b0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jns.2019.03.008","article-title":"Expanding the clinical description of autosomal recessive spastic ataxia of Charlevoix-Saguenay","volume":"400","author":"Briand","year":"2019","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1016\/j.jocn.2022.06.019_b0035","doi-asserted-by":"crossref","DOI":"10.1007\/s11940-019-0549-2","article-title":"The comprehensive management of cerebellar ataxia in adults","volume":"21","author":"Stephen","year":"2019","journal-title":"Curr Treat Options Neurol"},{"issue":"17","key":"10.1016\/j.jocn.2022.06.019_b0040","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1212\/WNL.0000000000000363","article-title":"Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"82","author":"Koppel","year":"2014","journal-title":"Neurology"},{"issue":"24","key":"10.1016\/j.jocn.2022.06.019_b0045","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jocn.2022.06.019_b0050","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.nmd.2021.01.003","article-title":"Characterization of cannabis use by patients with myotonic dystrophy type 1: a pilot study","volume":"31","author":"Beauchesne","year":"2021","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"10.1016\/j.jocn.2022.06.019_b0055","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.jocn.2022.06.019_b0060","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/MLR.0000000000000447","article-title":"A time trade-off-derived value set of the EQ-5D-5L for Canada","volume":"54","author":"Xie","year":"2016","journal-title":"Med Care"},{"issue":"3","key":"10.1016\/j.jocn.2022.06.019_b0065","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.healthpol.2018.01.009","article-title":"The Canadian Cannabis Act legalizes and regulates recreational cannabis use in 2018","volume":"122","author":"Cox","year":"2018","journal-title":"Health Policy"},{"key":"10.1016\/j.jocn.2022.06.019_b0070","first-page":"11","article-title":"What has changed since cannabis was legalized?","volume":"31","author":"Rotermann","year":"2020","journal-title":"Health Rep"},{"key":"10.1016\/j.jocn.2022.06.019_b0075","first-page":"111","article-title":"Simplified guideline for prescribing medical cannabinoids in primary care","volume":"64","author":"Allan","year":"2018","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.jocn.2022.06.019_b0080","unstructured":"Canadian Cannabis Survey 2021: Summary. Statistics Canada 2021. [Updated Dec 23 2021] Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-medication\/cannabis\/research-data\/canadian-cannabis-survey-2021-summary.html."},{"key":"10.1016\/j.jocn.2022.06.019_b0085","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3389\/fnmol.2019.00094","article-title":"Endocannabinoid system in spinocerebellar ataxia type-3 and other autosomal-dominant cerebellar ataxias: potential role in pathogenesis and expected relevance as neuroprotective targets","volume":"12","author":"Gomez-Ruiz","year":"2019","journal-title":"Front Mol Neurosci"},{"issue":"16","key":"10.1016\/j.jocn.2022.06.019_b0090","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1113\/JP271106","article-title":"Does modulation of the endocannabinoid system have potential therapeutic utility in cerebellar ataxia?","volume":"594","author":"Stephens","year":"2016","journal-title":"J Physiol"},{"key":"10.1016\/j.jocn.2022.06.019_b0095","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.bjp.0707003","article-title":"Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors","volume":"150","author":"Pryce","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jocn.2022.06.019_b0100","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jocn.2022.06.019_b0105","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-3-662-46450-2_7","article-title":"The role of the endocannabinoid system in pain","volume":"227","author":"Woodhams","year":"2015","journal-title":"Handb Exp Pharmacol"},{"issue":"9","key":"10.1016\/j.jocn.2022.06.019_b0110","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jpain.2016.05.010","article-title":"An exploratory human laboratory experiment evaluating vaporized cannabis in the treatment of neuropathic pain from spinal cord injury and disease","volume":"17","author":"Wilsey","year":"2016","journal-title":"J Pain"},{"key":"10.1016\/j.jocn.2022.06.019_b0115","unstructured":"National Academies of Sciences E, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. ed. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington (DC), 2017."},{"issue":"2","key":"10.1016\/j.jocn.2022.06.019_b0120","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF02444007","article-title":"Pain in multiple system atrophy","volume":"243","author":"Tison","year":"1996","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2022.06.019_b0125","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/AJP.0000000000000437","article-title":"Pain in extrapyramidal neurodegenerative diseases","volume":"33","author":"Yust-Katz","year":"2017","journal-title":"Clin J Pain"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586822002739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586822002739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:30:42Z","timestamp":1760823042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586822002739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":25,"alternative-id":["S0967586822002739"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2022.06.019","relation":{},"ISSN":["0967-5868"],"issn-type":[{"type":"print","value":"0967-5868"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabis use in patients with Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2022.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}